HOOK - HOOKIPA Pharma Inc.

-

$undefined

N/A

(N/A)

HOOKIPA Pharma Inc. NasdaqCM:HOOK HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company's immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers; Eseba-vec, an investigational immunotherapeutic agent in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers with enrollment completed in a Phase 1/2 clinical trial; and HB-300, which targets self-antigens for the treatment of prostate cancer. It is also developing HB-400 for the treatment of Hepatitis B that is in Phase I of clinical trial; and HB-500 for the treatment of Human Immunodeficiency Virus (HIV) that is in Phase I of clinical trial. The company has a collaboration and license agreement with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products for the treatment, cure, diagnosis, or prevention of the hepatitis B virus (HBV) and the HIV. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.

Location: 350 Fifth Avenue, New York, NY, 10118, United States | Website: https://www.hookipapharma.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-20.06M

Cash

40.28M

Avg Qtr Burn

-13.19M

Short % of Float

2.03%

Insider Ownership

0.13%

Institutional Own.

53.37%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Eseba-vec (HB-200) + pembrolizumab Details
Cancer, Human papillomavirus, HPV+ oropharyngeal cancer

Phase 2/3

Update

HB-400 Details
Hepatitis B

Phase 2

Data readout

Eseba-vec (HB-200) Details
Cancer, Human papillomavirus, Head and neck squamous cell carcinomas

Phase 2

Data readout

HB-202/HB-201 Details
Cancer, Human papillomavirus

Phase 1/2

Data readout

HB-500 Details
Human immunodeficiency virus

Phase 1b

Data readout

HB-700 Details
Cancer, Lung cancer, Colorectal cancer , Pancreatic cancer

Phase 1

Update

HB-300 Details
Cancer, Castration-resistant prostate cancer

Failed

Discontinued

HB-101 (VaxWave®) Details
Cytomegalovirus, Infectious disease, Kidney transplantation

Failed

Discontinued